Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

News SummaryMost relevantAll newsSector news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 08:20pm CEST

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN INC
10/26 MYLAN : Launches First Generics of Benicar® and Benicar HCT® Tablets
10/26 MYLAN : EpiPen Maker Mylan Hit With Class-Action Lawsuit
10/25 Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 Fr..
10/21 Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in My..
10/20 MYL NOTICE : Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline i..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/14 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Mylan N.V. In..
10/13 BERNSTEIN LIEBHARD LLP : Announces That A Suit Has Been Filed Against Mylan, N.V..
10/12 Investigation of Mylan N.V. Announced by Law Offices of Howard G. Smith
10/11 Rosen Law Firm Files Securities Class Action Lawsuit Against Mylan N.V. - MYL
More news
Sector news : Pharmaceuticals - NEC
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
10/26DJGlaxo Profit Jumps on Weaker Pound
10/26 Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close